Suppr超能文献

HlyA基因敲除产生了一种更安全的大肠杆菌A0 34/86变体,其在仔猪中的定殖能力未受影响。

HlyA knock out yields a safer Escherichia coli A0 34/86 variant with unaffected colonization capacity in piglets.

作者信息

Sheshko Valeria, Hejnova Jana, Rehakova Zuzana, Sinkora Jiri, Faldyna Martin, Alexa Pavel, Felsberg Jurgen, Nemcova Radomira, Bomba Alojz, Sebo Peter

机构信息

Laboratory of Molecular Biology of Bacterial Pathogens, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

出版信息

FEMS Immunol Med Microbiol. 2006 Nov;48(2):257-66. doi: 10.1111/j.1574-695X.2006.00140.x.

Abstract

Escherichia coli A0 34/86 (O83:K24:H31) has been successfully used for prophylactic and therapeutic intestinal colonization of premature and newborn infants, with the aim of preventing nosocomial infections. Although E. coli A0 34/86 was described as a nonpathogenic commensal, partial sequencing revealed that its genome harbours gene clusters highly homologous to virulence determinants of different types of E. coli, including closely linked genes of the alpha-haemolysin operon (hlyCABD) and for the cytotoxic necrotizing factor (cnf1). A haemolysin-deficient mutant (Delta hlyA) of E. coli A0 34/86 was generated and its colonization capacity was determined. The results show that a single dose of the A0 34/86 wild-type or Delta hlyA strains resulted in efficient intestinal colonization of newborn conventional piglets, and that this was still considerable after several weeks. No difference was observed between the wild-type and the mutant strains, showing that haemolysin expression does not contribute to intestinal colonization capacity of E. coli A0 34/86. Safety experiments revealed that survival of colostrum-deprived gnotobiotic newborn piglets was substantially higher upon colonization by the nonhaemolytic strain than following inoculation by its wild-type ancestor. We suggest that the E. coli A0 34/86 Delta hlyA mutant may represent a safer prophylactic and/or immunomodulatory tool with unaffected colonization capacity.

摘要

大肠杆菌A0 34/86(O83:K24:H31)已成功用于早产儿和新生儿的预防性和治疗性肠道定植,目的是预防医院感染。尽管大肠杆菌A0 34/86被描述为非致病性共生菌,但部分测序显示其基因组含有与不同类型大肠杆菌毒力决定因素高度同源的基因簇,包括α-溶血素操纵子(hlyCABD)和细胞毒性坏死因子(cnf1)的紧密连锁基因。构建了大肠杆菌A0 34/86的溶血素缺陷突变体(ΔhlyA)并测定其定植能力。结果表明,单剂量的A0 34/86野生型或ΔhlyA菌株可使新生常规仔猪有效肠道定植,且数周后仍相当可观。野生型和突变菌株之间未观察到差异,表明溶血素表达对大肠杆菌A0 34/86的肠道定植能力没有贡献。安全性实验表明,无溶血菌株定植后,初乳缺乏的无菌新生仔猪的存活率显著高于其野生型祖先接种后的存活率。我们认为,大肠杆菌A0 34/86 ΔhlyA突变体可能是一种更安全的预防性和/或免疫调节工具,其定植能力不受影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验